[HTML][HTML] Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib …
G Zhang, X Tang, X Zhang, X Qiu, Q Lai, J Li - Anti-Cancer Drugs, 2023 - journals.lww.com
The development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) represents a paradigm shift in the treatment of lung cancer with EGFR mutations …
(TKIs) represents a paradigm shift in the treatment of lung cancer with EGFR mutations …
Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib-induced …
G Zhang, X Tang, X Zhang, X Qiu, Q Lai… - Anti-cancer …, 2023 - pubmed.ncbi.nlm.nih.gov
The development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) represents a paradigm shift in the treatment of lung cancer with EGFR mutations …
(TKIs) represents a paradigm shift in the treatment of lung cancer with EGFR mutations …
[HTML][HTML] Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib …
G Zhang, X Tang, X Zhang, X Qiu, Q Lai, J Li - Anti-Cancer Drugs, 2023 - ncbi.nlm.nih.gov
The development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) represents a paradigm shift in the treatment of lung cancer with EGFR mutations …
(TKIs) represents a paradigm shift in the treatment of lung cancer with EGFR mutations …
Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib-induced …
G Zhang, X Tang, X Zhang, X Qiu, Q Lai, J Li - Anti-cancer Drugs, 2023 - europepmc.org
The development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) represents a paradigm shift in the treatment of lung cancer with EGFR mutations …
(TKIs) represents a paradigm shift in the treatment of lung cancer with EGFR mutations …
Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib-induced …
G Zhang, X Tang, X Zhang, X Qiu, Q Lai… - Anti-Cancer …, 2023 - ingentaconnect.com
The development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) represents a paradigm shift in the treatment of lung cancer with EGFR mutations …
(TKIs) represents a paradigm shift in the treatment of lung cancer with EGFR mutations …